The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.
Mishima Y et al. Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025.
Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D et al. Curr Opin Hematol. 2017 Apr 22. doi: 10.1097/MOH.0000000000000358. [Epub ahead of print].
Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.
Tatekawa S et al. Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14707. [Epub ahead of print].
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.
Pawlyn C et al. Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.
Natoni A et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.123. [Epub ahead of print].
Selective degradation of splicing factor CAPERα by anticancer sulfonamides.
Uehara T et al. Nat Chem Biol. 2017 Apr 24. doi: 10.1038/nchembio.2363. [Epub ahead of print].
MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.
Soley L et al. Curr Osteoporos Rep. 2017 Apr 21. doi: 10.1007/s11914-017-0360-5. [Epub ahead of print].
Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.
Hofman IJ et al. Haematologica. 2017 Apr 20. pii: haematol.2016.162198. doi: 10.3324/haematol.2016.162198. [Epub ahead of print].
Creating artificial lymphoid tissues to study immunity and hematological malignancies.
Shah SB et al. Curr Opin Hematol. 2017 Apr 19. doi: 10.1097/MOH.0000000000000356. [Epub ahead of print].
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Matyskiela ME et al. J Med Chem. 2017 Apr 20. doi: 10.1021/acs.jmedchem.6b01921. [Epub ahead of print].
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.
Quwaider D et al. J Hematol Oncol. 2017 Apr 18;10(1):92. doi: 10.1186/s13045-017-0461-8.
Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies.
Bui MH et al. Cancer Res. 2017 Apr 17. pii: canres.1793.2016. doi: 10.1158/0008-5472.CAN-16-1793. [Epub ahead of print].
Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression, an uncommon variant.
Hale DA et al. Proc (Bayl Univ Med Cent). 2017 Apr;30(2):192-194.
PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C et al. Oncotarget. 2017 Mar 29. doi: 10.18632/oncotarget.16642. [Epub ahead of print].
NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.
Hao M et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.115. [Epub ahead of print].
An ex vivo platform for the prediction of clinical response in multiple myeloma.
Silva AS et al. Cancer Res. 2017 Apr 11. pii: canres.0502.2017. doi: 10.1158/0008-5472.CAN-17-0502. [Epub ahead of print].
Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy.
Čáňová K et al. Acta Medica (Hradec Kralove). 2017 Apr 11. doi: 10.14712/18059694.2017.44. [Epub ahead of print].
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.
Wang X et al. J Med Chem. 2017 Apr 26. doi: 10.1021/acs.jmedchem.7b00418. [Epub ahead of print].
Ribonucleotide reductase large subunit (RRM1) as a novel therapeutic target in multiple myeloma.
Sagawa M et al. Clin Cancer Res. 2017 Apr 25. pii: clincanres.0263.2017. doi: 10.1158/1078-0432.CCR-17-0263. [Epub ahead of print].
Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.
Nielsen KR et al. Leuk Lymphoma. 2017 Apr 9:1-10. doi: 10.1080/10428194.2017.1306643. [Epub ahead of print].
Development of β-Hairpin Peptides for the Measurement of SCF-Family E3 Ligase Activity in Vitro via Ornithine Ubiquitination.
Houston KM et al. ACS Omega. 2017 Mar 31;2(3):1198-1206. doi: 10.1021/acsomega.7b00109. Epub 2017 Mar 29.
The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases.
Angi M et al. Hematol Oncol Stem Cell Ther. 2017 Mar 31. pii: S1658-3876(17)30033-X. doi: 10.1016/j.hemonc.2017.03.002. [Epub ahead of print].
Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.
Goodyear OC et al. Oncotarget. 2017 Mar 28. doi: 10.18632/oncotarget.16628. [Epub ahead of print].
Both mucosal- associated invariant and natural killer T cell deficiency in multiple myeloma can be countered by PD-1 inhibition.
Favreau M et al. Haematologica. 2017 Apr 6. pii: haematol.2017.163758. doi: 10.3324/haematol.2017.163758. [Epub ahead of print].
Bone marrow myeloid cells in regulation of multiple myeloma progression.
Herlihy SE et al. Cancer Immunol Immunother. 2017 Apr 4. doi: 10.1007/s00262-017-1992-0. [Epub ahead of print].
bFGF Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients.
Wróbel T et al. Anticancer Res. 2017 Apr;37(4):1799-1803.
RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC et al. Br J Haematol. 2017 Apr;177(1):80-94. doi: 10.1111/bjh.14525.
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.
Beldi-Ferchiou A et al. PLoS One. 2017 Apr 3;12(4):e0174835. doi: 10.1371/journal.pone.0174835. eCollection 2017.
PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
Ueno N et al. Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.79. [Epub ahead of print].
Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression.
Pang J et al. Haematologica. 2017 Mar 30. pii: haematol.2016.154062. doi: 10.3324/haematol.2016.154062. [Epub ahead of print].
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment.
Botta C et al. Curr Cancer Drug Targets. 2017 Mar 30. doi: 10.2174/1568009617666170330154756. [Epub ahead of print].
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
Piddock RE et al. Cancers (Basel). 2017 Mar 28;9(4). pii: E29. doi: 10.3390/cancers9040029.